Osporil (Zoledronic Acid)

Zoledronic Acid, the active ingredient in Osporil, is a bisphosphonate presented as a 5 mg/5 ml solution for intravenous use. It treats osteoporosis and other bone‑loss conditions in adults, including patients at high risk of fracture.

GNH USA supplies Osporil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Zoledronic Acid is used in clinical practice to manage disorders that affect bone remodeling and calcium metabolism. - Osteoporosis: reduces risk of vertebral and hip fractures in post‑menopausal women and men at high risk. - Paget’s disease of bone: normalises bone turnover and alleviates bone pain. - Bone metastases and hypercalcaemia of malignancy: lowers serum calcium and delays skeletal‑related events.

Adverse reactions to zoledronic acid vary in frequency and severity.

Common Side Effects: - Acute‑phase flu‑like symptoms: fever, myalgia, arthralgia. - Musculoskeletal pain: bone, joint or muscle discomfort. - Nausea or vomiting. - Transient elevation of serum creatinine. - Headache.

Serious or Rare Side Effects: - Severe renal impairment or acute kidney injury. - Osteonecrosis of the jaw (ONJ). - Atypical femoral fractures. - Hypocalcaemia. - Severe hypersensitivity reactions, including anaphylaxis.

When using zoledronic acid, clinicians should consider several safety measures. - Renal function assessment: evaluate baseline creatinine clearance before infusion. - Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk. - Dental health: perform oral examination and treat existing dental disease before therapy. - Concomitant nephrotoxic drugs: avoid or monitor use of NSAIDs, aminoglycosides, or contrast agents. - Pregnancy and lactation: contraindicated; avoid use in women who are pregnant or breastfeeding. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Zoledronic acid may interact with several co‑administered agents, requiring vigilance.

Major Interactions (Avoid): - Nephrotoxic agents such as high‑dose NSAIDs, aminoglycosides and iodinated contrast media. - Concomitant use of bisphlycer   ---

Moderate Interactions (Monitor Closely): - Calcium‑containing antacids or supplements taken within 4 h of the infusion.\n- Loop‑diuretics (e.g., furosemide) that may affect calcium balance. - Vitamin D analogues (calcitriol) that alter calcium metabolism. - Oral bisphosphonates administered concurrently.